vs
百利高（PRGO）与罗布乐思（RBLX）财务数据对比。点击上方公司名可切换其他公司
罗布乐思的季度营收约是百利高的1.3倍（$1.4B vs $1.1B），罗布乐思净利率更高（-22.3% vs -127.8%，领先105.5%），罗布乐思同比增速更快（43.2% vs -2.5%），罗布乐思自由现金流更多（$308.6M vs $148.6M），过去两年罗布乐思的营收复合增速更高（32.9% vs 1.3%）
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
罗布乐思（Roblox Corporation）是总部位于美国加利福尼亚州圣马特奥的游戏企业，由大卫·巴斯祖奇与埃里克·卡塞尔于2004年共同创立。公司核心产品为同名线上游戏创作平台Roblox，于2006年正式上线，截至2024年12月底全球员工规模已超2400人。
PRGO vs RBLX — 直观对比
营收规模更大
RBLX
是对方的1.3倍
$1.1B
营收增速更快
RBLX
高出45.7%
-2.5%
净利率更高
RBLX
高出105.5%
-127.8%
自由现金流更多
RBLX
多$160.0M
$148.6M
两年增速更快
RBLX
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.4B |
| 净利润 | $-1.4B | $-316.0M |
| 毛利率 | 32.6% | 77.7% |
| 营业利润率 | -116.0% | -25.3% |
| 净利率 | -127.8% | -22.3% |
| 营收同比 | -2.5% | 43.2% |
| 净利润同比 | -3093.9% | -43.9% |
| 每股收益（稀释后） | $-10.23 | $-0.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRGORBLX
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.0B | $1.4B | ||
| Q2 25 | $1.1B | $1.1B | ||
| Q1 25 | $1.0B | $1.0B | ||
| Q4 24 | $1.1B | $988.2M | ||
| Q3 24 | $1.1B | $919.0M | ||
| Q2 24 | $1.1B | $893.5M | ||
| Q1 24 | $1.1B | $801.3M |
净利润PRGORBLX
| Q4 25 | $-1.4B | $-316.0M | ||
| Q3 25 | $7.5M | $-255.6M | ||
| Q2 25 | $-8.4M | $-278.4M | ||
| Q1 25 | $-6.4M | $-215.1M | ||
| Q4 24 | $-44.4M | $-219.6M | ||
| Q3 24 | $-21.0M | $-239.3M | ||
| Q2 24 | $-108.4M | $-205.9M | ||
| Q1 24 | $2.0M | $-270.6M |
毛利率PRGORBLX
| Q4 25 | 32.6% | 77.7% | ||
| Q3 25 | 36.1% | 78.2% | ||
| Q2 25 | 34.4% | 78.2% | ||
| Q1 25 | 37.6% | 78.3% | ||
| Q4 24 | 33.9% | 77.9% | ||
| Q3 24 | 37.2% | 77.7% | ||
| Q2 24 | 37.0% | 77.8% | ||
| Q1 24 | 33.1% | 77.7% |
营业利润率PRGORBLX
| Q4 25 | -116.0% | -25.3% | ||
| Q3 25 | 7.0% | -21.8% | ||
| Q2 25 | 4.3% | -29.8% | ||
| Q1 25 | 4.5% | -24.6% | ||
| Q4 24 | 10.0% | -24.7% | ||
| Q3 24 | 7.4% | -30.4% | ||
| Q2 24 | -2.5% | -26.6% | ||
| Q1 24 | -5.1% | -37.7% |
净利率PRGORBLX
| Q4 25 | -127.8% | -22.3% | ||
| Q3 25 | 0.7% | -18.8% | ||
| Q2 25 | -0.8% | -25.8% | ||
| Q1 25 | -0.6% | -20.8% | ||
| Q4 24 | -3.9% | -22.2% | ||
| Q3 24 | -1.9% | -26.0% | ||
| Q2 24 | -10.2% | -23.0% | ||
| Q1 24 | 0.2% | -33.8% |
每股收益（稀释后）PRGORBLX
| Q4 25 | $-10.23 | $-0.44 | ||
| Q3 25 | $0.05 | $-0.37 | ||
| Q2 25 | $-0.06 | $-0.41 | ||
| Q1 25 | $-0.05 | $-0.32 | ||
| Q4 24 | $-0.32 | $-0.32 | ||
| Q3 24 | $-0.15 | $-0.37 | ||
| Q2 24 | $-0.79 | $-0.32 | ||
| Q1 24 | $0.01 | $-0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $3.1B |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | $2.9B | $394.5M |
| 总资产 | $8.5B | $9.6B |
| 负债/权益比越低杠杆越低 | — | 2.98× |
8季度趋势，按日历期对齐
现金及短期投资PRGORBLX
| Q4 25 | — | $3.1B | ||
| Q3 25 | $432.1M | $2.9B | ||
| Q2 25 | $454.2M | $2.6B | ||
| Q1 25 | $409.9M | $2.7B | ||
| Q4 24 | $558.8M | $2.4B | ||
| Q3 24 | $1.5B | $2.3B | ||
| Q2 24 | $542.8M | $2.4B | ||
| Q1 24 | $658.5M | $2.4B |
总债务PRGORBLX
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益PRGORBLX
| Q4 25 | $2.9B | $394.5M | ||
| Q3 25 | $4.4B | $407.6M | ||
| Q2 25 | $4.5B | $353.2M | ||
| Q1 25 | $4.4B | $310.7M | ||
| Q4 24 | $4.3B | $221.4M | ||
| Q3 24 | $4.6B | $189.9M | ||
| Q2 24 | $4.5B | $121.5M | ||
| Q1 24 | $4.7B | $71.6M |
总资产PRGORBLX
| Q4 25 | $8.5B | $9.6B | ||
| Q3 25 | $10.1B | $8.6B | ||
| Q2 25 | $10.1B | $7.8B | ||
| Q1 25 | $9.8B | $7.5B | ||
| Q4 24 | $9.6B | $7.2B | ||
| Q3 24 | $11.2B | $6.7B | ||
| Q2 24 | $10.4B | $6.5B | ||
| Q1 24 | $10.6B | $6.3B |
负债/权益比PRGORBLX
| Q4 25 | — | 2.98× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 5.48× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $175.4M | $607.0M |
| 自由现金流经营现金流 - 资本支出 | $148.6M | $308.6M |
| 自由现金流率自由现金流/营收 | 13.4% | 21.8% |
| 资本支出强度资本支出/营收 | 2.4% | 21.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $145.1M | $1.4B |
8季度趋势，按日历期对齐
经营现金流PRGORBLX
| Q4 25 | $175.4M | $607.0M | ||
| Q3 25 | $51.7M | $546.2M | ||
| Q2 25 | $75.9M | $199.3M | ||
| Q1 25 | $-64.5M | $443.9M | ||
| Q4 24 | $312.6M | $184.5M | ||
| Q3 24 | $42.2M | $247.4M | ||
| Q2 24 | $9.5M | $151.4M | ||
| Q1 24 | $-1.4M | $238.9M |
自由现金流PRGORBLX
| Q4 25 | $148.6M | $308.6M | ||
| Q3 25 | $29.8M | $443.6M | ||
| Q2 25 | $56.7M | $176.7M | ||
| Q1 25 | $-90.0M | $426.5M | ||
| Q4 24 | $274.9M | $120.6M | ||
| Q3 24 | $15.1M | $218.0M | ||
| Q2 24 | $-18.9M | $111.7M | ||
| Q1 24 | $-26.5M | $192.3M |
自由现金流率PRGORBLX
| Q4 25 | 13.4% | 21.8% | ||
| Q3 25 | 2.9% | 32.6% | ||
| Q2 25 | 5.4% | 16.3% | ||
| Q1 25 | -8.6% | 41.2% | ||
| Q4 24 | 24.2% | 12.2% | ||
| Q3 24 | 1.4% | 23.7% | ||
| Q2 24 | -1.8% | 12.5% | ||
| Q1 24 | -2.4% | 24.0% |
资本支出强度PRGORBLX
| Q4 25 | 2.4% | 21.1% | ||
| Q3 25 | 2.1% | 7.5% | ||
| Q2 25 | 1.8% | 2.1% | ||
| Q1 25 | 2.4% | 1.7% | ||
| Q4 24 | 3.3% | 6.5% | ||
| Q3 24 | 2.5% | 3.2% | ||
| Q2 24 | 2.7% | 4.4% | ||
| Q1 24 | 2.3% | 5.8% |
现金转化率PRGORBLX
| Q4 25 | — | — | ||
| Q3 25 | 6.89× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.70× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
RBLX
暂无分部数据
